Nanodomain-specific beta-blockers for the treatment of heart failure
Beta-blockers are among the most important drugs used to treat heart failure. They counteract excessive sympathetic signalling and can thereby slow harmful cardiac remodelling. At the same time, however, they can impair contraction and relaxation of the heart muscle. This may limit their use, particularly in patients whose hearts already have difficulty relaxing.
Researchers have identified subcellular mechanisms that could make it possible to separate these different effects of beta-receptor signalling. Based on these findings, they have developed a nanomedicine-based approach designed to selectively block harmful signals associated with cardiac remodelling while preserving the regulation of cardiac contraction and relaxation.
The project will investigate the pharmacokinetics and efficacy of this potential new generation of nanodomain-specific beta-blockers in a porcine model of heart failure. In parallel, human cardiac tissue slices obtained from surgical residual tissue will be studied. The aim is to determine whether this approach is suitable for further development towards clinical application.
- Project Term
- 2026 - 2029
- Granted Budget
- € 958.446
- Indication
- Heart failure
- Therapeutic Principle
- Drug
- Principal Investigator
- Nikolaev, Viacheslav (Universitätsklinikum Hamburg-Eppendorf)